Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis.

Del Paggio JC, Tannock IF.

Lancet Oncol. 2019 Aug;20(8):1065-1069. doi: 10.1016/S1470-2045(19)30338-9. Epub 2019 Jul 8.

PMID:
31296490
2.

Improving Treatment for Advanced Prostate Cancer.

Tannock IF.

N Engl J Med. 2019 Jul 11;381(2):176-177. doi: 10.1056/NEJMe1906363. No abstract available.

PMID:
31291522
3.

Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.

Eur Urol Oncol. 2019 Jul;2(4):448-455. doi: 10.1016/j.euo.2018.10.003. Epub 2018 Nov 5. Review.

PMID:
31277782
4.

Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?

Vera-Badillo FE, Tannock IF, Booth CM.

J Clin Oncol. 2019 Jul 1:JCO1802257. doi: 10.1200/JCO.18.02257. [Epub ahead of print] No abstract available.

PMID:
31260641
5.

Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hansen AR, Tannock IF, Templeton A, Chen E, Evans A, Knox J, Prawira A, Sridhar SS, Tan S, Vera-Badillo F, Wang L, Wouters BG, Joshua AM.

Oncologist. 2019 Apr 5. pii: theoncologist.2018-0621. doi: 10.1634/theoncologist.2018-0621. [Epub ahead of print]

PMID:
30952818
6.

Molecular screening to select therapy for advanced cancer?

Tannock IF, Hickman JA.

Ann Oncol. 2019 May 1;30(5):661-663. doi: 10.1093/annonc/mdz088. No abstract available.

PMID:
30865225
7.

Disclosure-in the blink of an eye.

Tannock IF.

Ann Oncol. 2019 Feb 1;30(2):169-170. doi: 10.1093/annonc/mdy543. No abstract available.

PMID:
30596811
8.

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK.

J Clin Oncol. 2019 Feb 10;37(5):403-410. doi: 10.1200/JCO.18.01279. Epub 2018 Dec 21.

PMID:
30576268
9.

Avoiding the hazards of misinterpreting treatment effects.

Saad ED, Tannock IF.

Ann Oncol. 2019 Jan 1;30(1):16-18. doi: 10.1093/annonc/mdy472. No abstract available.

PMID:
30346470
10.

Low-Fat Abiraterone Food Effect Is of Great Consequence.

Tannock IF.

J Clin Oncol. 2018 Oct 20;36(30):3058-3059. doi: 10.1200/JCO.2018.79.2358. Epub 2018 Sep 6. No abstract available.

PMID:
30188783
11.

Purchasing silence.

Tannock IF, Joshua AM.

Ann Oncol. 2018 Jun 1;29(6):1339-1340. doi: 10.1093/annonc/mdy131. No abstract available.

PMID:
29648577
12.

Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer.

Vardy JL, Dhillon HM, Pond GR, Renton C, Clarke SJ, Tannock IF.

ESMO Open. 2018 Feb 14;3(2):e000302. doi: 10.1136/esmoopen-2017-000302. eCollection 2018.

13.

Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer.

Niraula S, Templeton AJ, Vera-Badillo F, Dodd A, Nugent Z, Joshua AM, Tannock IF.

Future Sci OA. 2017 Oct 20;4(1):FSO253. doi: 10.4155/fsoa-2017-0094. eCollection 2018 Jan.

14.

Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.

Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE.

Cancer Treat Rev. 2018 Jan;62:1-8. doi: 10.1016/j.ctrv.2017.10.008. Epub 2017 Oct 31. Review.

PMID:
29126017
15.

Neurobiological Mechanisms of Chemotherapy-induced Cognitive Impairment in a Transgenic Model of Breast Cancer.

Winocur G, Berman H, Nguyen M, Binns MA, Henkelman M, van Eede M, Piquette-Miller M, Sekeres MJ, Wojtowicz JM, Yu J, Zhang H, Tannock IF.

Neuroscience. 2018 Jan 15;369:51-65. doi: 10.1016/j.neuroscience.2017.10.048. Epub 2017 Nov 4.

PMID:
29113931
16.

Abiraterone in Metastatic Prostate Cancer.

Tannock IF.

N Engl J Med. 2017 Oct 26;377(17):1695. doi: 10.1056/NEJMc1711029. No abstract available.

PMID:
29083123
17.

Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy.

Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL.

J Cancer Surviv. 2018 Apr;12(2):178-185. doi: 10.1007/s11764-017-0656-6. Epub 2017 Oct 27.

PMID:
29080061
18.

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.

Del Paggio JC, Sullivan R, Schrag D, Hopman WM, Azariah B, Pramesh CS, Tannock IF, Booth CM.

Lancet Oncol. 2017 Jul;18(7):887-894. doi: 10.1016/S1470-2045(17)30415-1. Epub 2017 Jun 2.

PMID:
28583794
19.

A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer.

Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, Dodd A, Crawley A, Tannock IF.

Brain Imaging Behav. 2019 Feb;13(1):15-26. doi: 10.1007/s11682-017-9728-5.

PMID:
28466438
20.

Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.

Tan Q, Joshua AM, Wang M, Bristow RG, Wouters BG, Allen CJ, Tannock IF.

Cancer Chemother Pharmacol. 2017 May;79(5):959-969. doi: 10.1007/s00280-017-3298-5. Epub 2017 Apr 4.

PMID:
28378028
21.

Limits to Precision Cancer Medicine.

Tannock IF, Hickman JA.

N Engl J Med. 2017 Jan 5;376(1):96-7. doi: 10.1056/NEJMc1613563. No abstract available.

PMID:
28052222
22.

Can modelling of PSA dynamics accelerate drug development for prostate cancer?

Tannock IF.

Lancet Oncol. 2017 Jan;18(1):16-18. doi: 10.1016/S1470-2045(16)30641-6. Epub 2016 Dec 13. No abstract available.

PMID:
27979601
23.

Relevance of randomised controlled trials in oncology.

Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F.

Lancet Oncol. 2016 Dec;17(12):e560-e567. doi: 10.1016/S1470-2045(16)30572-1. Review.

PMID:
27924754
24.

Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?

Del Paggio JC, Azariah B, Sullivan R, Hopman WM, James FV, Roshni S, Tannock IF, Booth CM.

Ann Oncol. 2017 Jan 1;28(1):157-162. doi: 10.1093/annonc/mdw538.

PMID:
27742650
25.

Limits to Personalized Cancer Medicine.

Tannock IF, Hickman JA.

N Engl J Med. 2016 Sep 29;375(13):1289-94. doi: 10.1056/NEJMsb1607705. No abstract available.

PMID:
27682039
26.

Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.

Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA.

Cancer. 2017 Jan 1;123(2):237-244. doi: 10.1002/cncr.30320. Epub 2016 Sep 1.

27.

Honorary and ghost authorship in reports of randomised clinical trials in oncology.

Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF.

Eur J Cancer. 2016 Oct;66:1-8. doi: 10.1016/j.ejca.2016.06.023. Epub 2016 Aug 6.

PMID:
27500368
28.

Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.

Vardy JL, Dhillon HM, Pond GR, Renton C, Dodd A, Zhang H, Clarke SJ, Tannock IF.

Ann Oncol. 2016 Sep;27(9):1761-7. doi: 10.1093/annonc/mdw252. Epub 2016 Jul 20.

29.

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Mirtti T, van Rhijn B, Fleshner NE, Finelli A, Laato M, Jewett MA, Moore MJ, Sridhar S, Nurmi M, Tannock IF, Zlotta AR.

Bladder Cancer. 2016 Apr 27;2(2):263-272.

30.

Environmental enrichment protects against cognitive impairment following chemotherapy in an animal model.

Winocur G, Wojtowicz JM, Merkley CM, Tannock IF.

Behav Neurosci. 2016 Aug;130(4):428-36. doi: 10.1037/bne0000155. Epub 2016 Jun 23.

PMID:
27337062
31.

Under-reporting of harm in clinical trials.

Seruga B, Templeton AJ, Badillo FE, Ocana A, Amir E, Tannock IF.

Lancet Oncol. 2016 May;17(5):e209-19. doi: 10.1016/S1470-2045(16)00152-2. Epub 2016 Apr 27. Review.

PMID:
27301048
32.

The five Rs of chemotherapy.

Tannock IF.

Lancet Oncol. 2016 Jun;17(6):703-705. doi: 10.1016/S1470-2045(16)00103-0. No abstract available.

PMID:
27299264
33.

Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors.

Tan Q, Wang M, Yu M, Zhang J, Bristow RG, Hill RP, Tannock IF.

Neoplasia. 2016 Jun;18(6):347-55. doi: 10.1016/j.neo.2016.04.003.

34.

Toward Value-Based Pricing to Boost Cancer Research and Innovation.

Ocana A, Amir E, Tannock IF.

Cancer Res. 2016 Jun 1;76(11):3127-9. doi: 10.1158/0008-5472.CAN-15-3179. Epub 2016 May 16.

35.

Bias in reporting of randomised clinical trials in oncology.

Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF.

Eur J Cancer. 2016 Jul;61:29-35. doi: 10.1016/j.ejca.2016.03.066. Epub 2016 May 3.

PMID:
27151552
36.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2016 May 2. pii: mdw180. [Epub ahead of print] No abstract available.

PMID:
27141017
37.

Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls.

Yao C, Rich JB, Tannock IF, Seruga B, Tirona K, Bernstein LJ.

J Int Neuropsychol Soc. 2016 May;22(5):530-9. doi: 10.1017/S1355617716000126. Epub 2016 Mar 10.

PMID:
26960672
38.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ.

J Clin Oncol. 2016 May 10;34(14):1652-9. doi: 10.1200/JCO.2015.65.7270. Epub 2016 Mar 7.

39.

A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.

Manokumar T, Aziz S, Breunis H, Rizvi SF, Joshua AM, Tannock IF, Alibhai SM.

J Geriatr Oncol. 2016 Mar;7(2):81-9. doi: 10.1016/j.jgo.2016.01.003. Epub 2016 Feb 4.

PMID:
26853769
40.

Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.

Niraula S, Templeton AJ, Vera-Badillo FE, Joshua AM, Sridhar SS, Cheung PW, Yip PM, Dodd A, Nugent Z, Tannock IF.

Prostate. 2016 Feb;76(2):235-42. doi: 10.1002/pros.23117. Epub 2015 Nov 2.

PMID:
26768279
41.

Harms of Intermittent vs Continuous Androgen-Deprivation Therapy for Prostate Cancer.

Niraula S, Tannock IF.

JAMA Oncol. 2016 Apr;2(4):461-2. doi: 10.1001/jamaoncol.2015.4682. No abstract available.

PMID:
26720183
42.

Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy.

Tannock IF, Sternberg CN.

Ann Oncol. 2016 Mar;27(3):545-6. doi: 10.1093/annonc/mdv600. Epub 2015 Dec 12. No abstract available.

PMID:
26659397
43.

Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study.

Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF.

J Clin Oncol. 2015 Dec 1;33(34):4085-92. doi: 10.1200/JCO.2015.63.0905. Epub 2015 Nov 2.

44.

Failures in Phase III: Causes and Consequences.

Seruga B, Ocana A, Amir E, Tannock IF.

Clin Cancer Res. 2015 Oct 15;21(20):4552-60. doi: 10.1158/1078-0432.CCR-15-0124. Review.

45.

Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them.

Tan Q, Saggar JK, Yu M, Wang M, Tannock IF.

Cancer J. 2015 Jul-Aug;21(4):254-62. doi: 10.1097/PPO.0000000000000131. Review.

PMID:
26222076
46.

Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.

Yu M, Lee C, Wang M, Tannock IF.

Cancer Sci. 2015 Oct;106(10):1438-47. doi: 10.1111/cas.12756. Epub 2015 Sep 25.

47.

Benefits of Adjuvant Chemotherapy for Bladder Cancer.

Booth CM, Tannock IF.

JAMA Oncol. 2015 Sep;1(6):727-8. doi: 10.1001/jamaoncol.2015.1210. No abstract available.

PMID:
26181353
48.

Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.

Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E.

J Clin Pathol. 2015 Oct;68(10):839-43. doi: 10.1136/jclinpath-2015-203012. Epub 2015 Jun 15.

PMID:
26076967
49.

The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation.

Stapleton S, Milosevic M, Tannock IF, Allen C, Jaffray DA.

J Control Release. 2015 Aug 10;211:163-70. doi: 10.1016/j.jconrel.2015.06.008. Epub 2015 Jun 10.

PMID:
26070245
50.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2015 Aug;26(8):1589-604. doi: 10.1093/annonc/mdv257. Epub 2015 Jun 3.

Supplemental Content

Loading ...
Support Center